Skip to main content

Harmon Cyrus's Form 4 filing

Olema Pharmaceuticals, Inc. (OLMA) · filed Sep 18, 2025

Accession no.
0001831410-25-000004
Filed
Sep 18, 2025
Trade date
Sep 16-18, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market sales total $204.8K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Harmon CyrusCIK 0001831410Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 16, 2025Common StockSSaleDisposed−10,000$8.04F1−$80,400754,140Direct
Sep 18, 2025Common StockSSaleDisposed−10,000$8.33F2−$83,300744,140Direct
Sep 16, 2025Common StockSSaleDisposed−1,914$8.08F3−$15,465.12120,114Indirect
Sep 18, 2025Common StockSSaleDisposed−3,086$8.32F5−$25,675.52117,028Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The weighted average sale price for the transaction reported was $8.04, and the range of prices was between $8.02 and $8.09. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

F2

The weighted average sale price for the transaction reported was $8.33, and the range of prices was between $8.28 and $8.37. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

F3

The weighted average sale price for the transaction reported was $8.08, and the range of prices was between $8.04 and $8.08. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

F5

The weighted average sale price for the transaction reported was $8.32, and the range of prices was between $8.29 and $8.33. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)